Mitroflow Heart Valve: 5.5 Years Clinical Experience

Abstract

From March 1982 through December 1986, 139 Mitroflow pericardial heart valves were utilized in 129 patients. There were 69 males and 60 females, with an average age of 55.2, range 26 to 74 years. Eighty-nine patients underwent isolated aortic valve replacements, 27 isolated mitral valve replacements, 3 isolated tricuspid valve replacements, 10 mitro-aortic valve replacements. In 27 cases (20.9%) additional cardiac surgery was performed. Maximum follow-up was 5.5 years with a mean of 37.9 months. The cumulative follow-up was 407.25 patient-years. Overall hospital mortality was 1.6% (2 cases). There were 3 late deaths in this series (2.4%). The linearized incidence of late mortality was 0.49% per patient-year. The survival actuarial curve was 96% +/- 1.8. The incidence of thromboembolism was 1.22% per patient-year, and the actuarial thromboembolism-free rates was 93% +/- 2.7. Prosthetic endocarditis occurred in one patient. Three patients developed primary tissue failure of the Mitroflow valve in the mitral position. The linearized incidence of primary tissue failure was 0.73% per patient-year and the actuarial freedom from primary tissue failure was 95% +/- 3.2. A total of 4 patients underwent reoperation (0.49% per patient-year). In conclusion, the clinical performance of the Mitroflow pericardial heart valve at medium-term follow-up is satisfactory, however a significant number of early mitral primary tissue failures have already occurred.

Early Structural Valve Deterioration of Mitroflow Aortic Bioprosthesis

“…In fact, numerous elderly patients are denied surgery because of the high risk of major adverse events related to repeat surgery. 15,16 In view of the potential impact of early SVD in elderly patients, the present study was thus designed (1) to assess in a large cohort of patients the incidence of SVD for Mitroflow aortic pericardial bioprosthesis (12A/LX) based on echocardiography; (2) to characterize the pattern and the temporal course of SVD; and finally (3) to assess the correlates of SVD and its impact on patient prognosis.…”